reference/28907881

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28907881

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	3004
issn	1557-3265 1078-0432
issueIdentifier	9
pageRange	2997-3004
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	2997
bibliographicCitation	Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 01;17(9):2997–3004. doi: 10.1158/1078-0432.ccr-10-3425. PMID: 21415214.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_886674cdb18056307d07107641bbb58a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9f8e8bc209623d1cec03db8d46a74dc7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7115dfc8589461391489940210142bf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bd8d41d3e7d9442ced60ac3ffbcb2ce2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0f4025e2f32589cd78433b77245456f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_966ff4d4dac73e5568c39df64d4db4ee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d6f51cb2f0ec983119a108ca80dbc84 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c43bdf3eb8a53582ad24a9d66d128f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_154b9f8506531d8a3a3e6aadd2402ed4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f837ad8f02aa3c73b7200caa219031a3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_02168b01e2e8266f3623398352adcd1b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_90b6dbe0d02ea6677d847f8c04786b6e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fba98151d07204617b48ab7aff084e35 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3753a2f7e9b9e49c506ac08ee3e9e7d8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a258b4c0f450cf0f3cbc2e3b9d2e586
date	2011-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1158/1078-0432.ccr-10-3425 https://pubmed.ncbi.nlm.nih.gov/21415214
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794 https://portal.issn.org/resource/ISSN/1078-0432 https://portal.issn.org/resource/ISSN/1557-3265
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
discusses	http://id.nlm.nih.gov/mesh/M0014907 http://id.nlm.nih.gov/mesh/M0550416 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0016714 http://id.nlm.nih.gov/mesh/M0017642
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009593Q000493 http://id.nlm.nih.gov/mesh/D009593Q000009 http://id.nlm.nih.gov/mesh/D010752Q000627 http://id.nlm.nih.gov/mesh/D010752Q000493 http://id.nlm.nih.gov/mesh/D009593Q000627 http://id.nlm.nih.gov/mesh/D010752Q000009 http://id.nlm.nih.gov/mesh/D009369Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011355Q000627 http://id.nlm.nih.gov/mesh/D011355Q000493 http://id.nlm.nih.gov/mesh/D011355Q000008 http://id.nlm.nih.gov/mesh/D008954 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D011355Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D009593Q000008 http://id.nlm.nih.gov/mesh/D000970Q000493 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D015687Q000187 http://id.nlm.nih.gov/mesh/D020714 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D009369Q000473 http://id.nlm.nih.gov/mesh/D015687Q000502 http://id.nlm.nih.gov/mesh/D009369Q000378 http://id.nlm.nih.gov/mesh/D010752Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID132324 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID100427 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8976 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9581 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71464628 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11136 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6914 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_42cfbcd47747eec326f49bd492e9a41a http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11984561 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7947

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID252166895

Total number of triples: 89.